Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 703-712

  Kootte, Ruud S ^a   Smits, Loek P ^a   Van Der Valk, Fleur M ^a   Dasseux, Jean Louis ^b   Keyserling, Constance H ^b   Barbaras, Ronald ^b   Paolini, John F ^a   Santos, Raul D ^c   Van Dijk, Theo H ^d   Dallinga van Thie, Geesje M ^a   Nederveen, Aart J ^a   Mulder, Willem J M ^a   Hovingh, G Kees ^a   Kastelein, John J P ^a   Groen, Albert K ^d   Stroes, Erik S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Cerenis Therapeutics Holdings   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; DIPALMITOYLPHOSPHATIDYLGLYCEROL; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; RECOMBINANT APOLIPOPROTEIN A1; SPHINGOMYELIN; UNCLASSIFIED DRUG; CER-001; PHOSPHOLIPID; RECOMBINANT PROTEIN;

ADULT; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; FAMILIAL HYPOALPHALIPOPROTEINEMIA; FECAL STEROL EXCRETION; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; STEROL EXCRETION; BLOOD; CLINICAL TRIAL; HYPOALPHALIPOPROTEINEMIAS; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY;

ADULT; APOLIPOPROTEIN A-I; CAROTID ARTERIES; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPOALPHALIPOPROTEINEMIAS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PHOSPHOLIPIDS; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT PROTEINS;

EID: 84925299931     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M055665     Document Type: Article

References (49)

1. Fruchart, J-C., J. Davignon, M. P. Hermans, K. Al-Rubeaan, P. Amarenco, G. Assmann, P. Barter, J. Betteridge, E. Bruckert, A. Cuevas, et al. 2014. Residual macrovascular risk in 2013: what have we learned? Cardiovasc. Diabetol. 13 : 26.
2. Emerging Risk Factors Collaboration, Di Angelantonio, E., N. Sarwar, P. Perry, S. Kaptoge, K. K. Ray, A. Thompson, A. M. Wood, S. Lewington, N. Sattar, et al. 2009. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302 : 1993-2000.
3. Kannel, W. B., W. P. Castelli, and T. Gordon. 1979. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann. Intern. Med. 90 : 85-91.
4. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367 : 2089-2099.
5. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365 : 2255-2267.
6. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Hólm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet. 380 : 572-580.
7. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108 : 661-663.
8. Duverger, N., H. Kruth, F. Emmanuel, J. M. Caillaud, C. Viglietta, G. Castro, A. Tailleux, C. Fievet, J. C. Fruchart, L. M. Houdebine, et al. 1996. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 94 : 713-717.
9. Holleboom, A. G., L. Jakulj, R. Franssen, J. Decaris, M. Vergeer, J. Koetsveld, J. Luchoomun, A. Glass, M. K. Hellerstein, J. J. Kastelein, et al. 2013. In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J. Lipid Res. 54 : 1964-1971.
10. Bochem, A. E., D. F. van Wijk, A. G. Holleboom, R. Duivenvoorden, M. M. Motazacker, G. M. Dallinga-Thie, E. de Groot, J. J. Kastelein, A. J. Nederveen, G. K. Hovingh, et al. 2013. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur. Heart J. 34 : 286-291.
11. Duivenvoorden, R., A. G. Holleboom, B. van den Bogaard, A. J. Nederveen, E. de Groot, B. A. Hutten, A. W. Schimmel, G. K. Hovingh, J. J. Kastelein, J. A. Kuivenhoven, et al. 2011. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging. J. Am. Coll. Cardiol. 58 : 2481-2487. [Erratum. 2012. J. Am. Coll. Cardiol. 59: 196.]
12. Eriksson, M., L. A. Carlson, T. A. Miettinen, and B. Angelin. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation. 100 : 594-598.
13. Nanjee, M. N., C. J. Cooke, R. Garvin, F. Semeria, G. Lewis, W. L. Olszewski, and N. E. Miller. 2001. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. 42 : 1586-1593.
14. Shaw, J. A., A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart. 2008. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103 : 1084-1091.
15. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290 : 2292-2300.
16. Tardif, J-C., J. Grégoire, P. L. L'Allier, R. Ibrahim, J. Lespérance, T. M. Heinonen, S. Kouz, C. Berry, R. Basser, M. A. Lavoie, et al. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 297 : 1675-1682.
17. Tardif, J-C., C. M. Ballantyne, P. Barter, J-L. Dasseux, Z. A. Fayad, M-C. Guertin, J. J. Kastelein, C. Keyserling, H. Klepp, W. Koenig, et al. 2014. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. 35 : 3277-3286.
18. Goffinet, M., R. Baron, C. Tardy, G. Sy, A. Schwendeman, C. H. Keyserling, J. Wetterau, R. Barbaras, N. Lalwani, and J-L. Dasseux. 2011. CER-001, a new generation of HDL mimetic: characterization and determination of in vitro and in vivo activities; ATVB Scientific Sessions. P364.
19. de la Llera-Moya, M., D. Drazul-Schrader, B. F. Asztalos, M. Cuchel, D. J. Rader, and G. H. Rothblat. 2010. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30 : 796-801.
20. Heinemann, T., G-a. Kullak-Ublick, B. Pietruck, and K. Bergmann. 1991. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Eur. J. Clin. Pharmacol. 40 : S59-S63.
21. Arca, M., A. Montali, S. Ciocca, F. Angelico, and A. Cantafora. 1983. An improved gas-liquid chromatographic method for the determination of fecal neutral sterols. J. Lipid Res. 24 : 332-335.
22. Setchell, K. D., A. M. Lawson, N. Tanida, and J. Sjövall. 1983. General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. J. Lipid Res. 24 : 1085-1100.
23. Duivenvoorden, R., E. de Groot, B. M. Elsen, J. S. Laméris, R. J. van der Geest, E. S. Stroes, J. J. Kastelein, and A. J. Nederveen. 2009. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ. Cardiovasc. Imaging. 2 : 235-242.
24. Tawakol, A., R. Q. Migrino, G. G. Bashian, S. Bedri, D. Vermylen, R. C. Cury, D. Yates, G. M. LaMuraglia, K. Furie, S. Houser, et al. 2006. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48 : 1818-1824.
25. Rudd, J. H. F., K. S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, and Z. A. Fayad. 2007. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol. 50 : 892-896.
26. Fayad, Z. A., V. Mani, M. Woodward, D. Kallend, M. Abt, T. Burgess, V. Fuster, C. M. Ballantyne, E. A. Stein, J. C. Tardif, et al. 2011. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 378 : 1547-1559.
27. Björnsson, E. 2006. Drug-induced liver injury: Hy's rule revisited. Clin. Pharmacol. Ther. 79 : 521-528.
28. Jonas A. 2000. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta. 1529 : 245-256.
29. Kontush, A., E. C. de Faria, S. Chantepie, and M. J. Chapman. 2004. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler. Thromb. Vasc. Biol. 24 : 526-533.
30. Wang Y, J. F. P. Berbée, E. S. Stroes, J. W. Smit, L. M. Havekes, J. A. Romijn, and P. C. Rensen. 2011. CETP expression reverses the reconstituted HDL-induced increase in VLDL. J. Lipid Res. 52 : 1533-1541.
31. Tardy C., M. Goffinet, N. Boubekeur, R. Ackermann, G. Sy, A. Bluteau, G. Cholez, C. Keyserling, N. Lalwani, J. F. Paolini, et al. CER-001, an HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 232 : 110-118.
32. Shah, P. K., J. Yano, O. Reyes, K-Y. Chyu, S. Kaul, C. L. Bisgaier, S. Drake, and B. Cercek. 2001. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 103 : 3047-3050.
33. Jiao, S., T. G. Cole, R. T. Kitchens, B. Pfleger, and G. Schonfeld. 1990. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. Metabolism. 39 : 155-160.
34. Diditchenko, S., A. Gille, I. Pragst, D. Stadler, M. Waelchli, R. Hamilton, A. Leis, and S. D. Wright. 2013. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33 : 2202-2211.
35. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364 : 127-135.
36. Wang, X., H. L. Collins, M. Ranalletta, I. V. Fuki, J. T. Billheimer, G. H. Rothblat, A. R. Tall, and D. J. Rader. 2007. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117 : 2216-2224.
37. Rohatgi, A., A. Khera, J. D. Berry, E. G. Givens, C. R. Ayers, K. E. Wedin, I. J. Neeland, I. S. Yuhanna, D. R. Rader, J. A. de Lemos, et al. 2014. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371 : 2383-2393.
38. Rosenson R. S., H. B. Brewer Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125 : 1905-1919.
39. Nicholls, S. J., B. Cutri, S. G. Worthley, P. Kee, K-A. Rye, S. Bao, and P. J. Barter. 2005. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 25 : 2416-2421.
40. Waksman, R., R. Torguson, K. M. Kent, A. D. Pichard, W. O. Suddath, L. F. Satler, B. D. Martin, T. J. Perlman, J. A. Maltais, N. J. Weissman, et al. 2010. A first-in-man, randomized, placebocontrolled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 55 : 2727-2735.
41. Rye, K-A., and P. J. Barter. 2014. Cardioprotective functions of HDLs. J. Lipid Res. 55 : 168-179.
42. Westerterp, M., A. E. Bochem, L. Yvan-Charvet, A. J. Murphy, N. Wang, and A. R. Tall. 2014. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 114 : 157-170.
43. Feig, J. E., S. Parathath, J. X. Rong, S. L. Mick, Y. Vengrenyuk, L. Grauer, S. G. Young, and E. A. Fisher. 2011. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation. 123 : 989-998.
44. van Wijk, D. F., B. Sjouke, A. Figueroa, H. Emami, F. M. van der Valk, M. H. MacNabb, L. C. Hemphill, D. M. Schulte, M. G. Koopman, M. E. Lobatto, et al. 2014. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J. Am. Coll. Cardiol. 64 : 1418-1426.
45. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Buga, G. Hough, A. C. Wagner, and A. M. Fogelman. 2012. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler. Thromb. Vasc. Biol. 32 : 2553-2560.
46. Haase, C. L., R. Frikke-Schmidt, B. G. Nordestgaard, and A. Tybjærg-Hansen. 2012. Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet. 8 : e1003063.
47. Haase, C. L., A. Tybjærg-Hansen, A. A. Qayyum, J. Schou, B. G. Nordestgaard, and R. Frikke-Schmidt. 2012. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J. Clin. Endocrinol. Metab. 97 : E248-E256.
48. Frikke-Schmidt, R., B. G. Nordestgaard, M. C. A. Stene, A. A. Sethi, A. T. Remaley, P. Schnohr, P. Grande, and A. Tybjaerg-Hansen. 2008. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 299 : 2524-2532.
49. Davidson, M. H., J. Voogt, J. Luchoomun, J. Decaris, S. Killion, D. Boban, A. Glass, H. Mohammad, Y. Lu, D. Villegas, et al. 2013. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 230 : 322-329.